PD-L1 inhibitors, including the already marketed tislelizumab, nivolumab, and pembrolizumab, have shown significant efficacy in tumors, particularly small cell lung cancer and liver cancer (Liu and Wu, 2020; Wang et al., 2021). This evidence concerns the gene CD274 and small cell lung carcinoma.